治療前列腺癌藥物 Masitinib 獲頒新專利
New Patent Granted for Prostate Cancer Drug Masitinib
Updated at: June 18, 2026 at 02:01 AM
腫瘤學領域出現重大突破，AB Science SA 公司針對其領先化合物「馬賽替尼」(masitinib) 取得了美國專利，該藥物旨在治療轉移性去勢抗性前列腺癌 (mCRPC)。
A significant breakthrough in oncology has emerged as AB Science SA secured a U.S. patent for its lead compound, masitinib, targeting metastatic castrate-resistant prostate cancer (mCRPC).
此項專利有效期限至 2042 年，對於已近二十年未見新式聯合療法的領域而言，標誌著一個關鍵時刻。
This patent, valid until 2042, marks a pivotal moment for a field that has seen no new combination therapies for nearly two decades.
馬賽替尼是一種蛋白激酶抑制劑，預計與多西他賽 (docetaxel) 合併使用。
Masitinib works as a protein kinase inhibitor, intended to be used alongside docetaxel.
此療法與眾不同之處在於對精準醫療的承諾。
What sets this treatment apart is its commitment to precision medicine.
透過利用特定的生物標記——基線鹼性磷酸酶 (ALP) 數值，研究人員能夠識別出最有可能對該療法產生反應的患者。
By utilizing a specific biomarker—baseline alkaline phosphatase (ALP) levels—researchers can identify patients who are most likely to respond to the therapy.
第三期臨床試驗 AB12003 的數據顯示，對於 ALP 數值不高於 250 IU/L 的患者，其疾病惡化風險降低了 21%。
Clinical data from the Phase 3 AB12003 study showed a 21% reduction in disease progression risk for patients with ALP levels at or below 250 IU/L.
隨著美國食品藥物管理局 (FDA) 與歐洲藥品管理局 (EMA) 批准確認性的第三期臨床試驗 (AB22007)，這項進展為美歐兩地數以千計面臨此病症的患者帶來了新希望。
With regulatory bodies like the FDA and EMA authorizing a confirmatory Phase 3 trial (AB22007), this development offers new hope for the thousands of patients in the U.S. and Europe facing this condition.
長期的專利保護提供了進行大規模臨床試驗所需的穩定性，標誌著醫療界正朝向個人化、以生物標記為導向的癌症護理邁出充滿希望的一步。
The long-term patent protection provides the stability needed for large-scale clinical trials, signaling a hopeful shift toward personalized, biomarker-driven cancer care.
